Metraipolis › archive › dc_97e918b73bc2

Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study — Europe PMC PMID:41601658

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41601658
DOI
10.3389/fimmu.2025.1741564
License (as archived)
solo-consultazione
Archived
2026-11-06T21:21:30.209Z
SHA-256 of the archived text
a2e4b180e5d0ca6b41eb109e0f4ce35558fc34779a87691a64c65a5b06162bd0
Stable URL of this page
https://metraipolis.com/documento/dc_97e918b73bc2

How to cite

Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study — Europe PMC PMID:41601658 — Europe PMC (en), https://europepmc.org/article/MED/41601658 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97e918b73bc2 (Metraipolis archive dc_97e918b73bc2, sha256 a2e4b180e5d0ca6b41eb109e0f4ce35558fc34779a87691a64c65a5b06162bd0)
BibTeX
@misc{dc97e918b73bc2,
  title = {Efficacy and safety of zuberitamab in the treatment of primary membranous nephropathy: an observational study — Europe PMC PMID:41601658},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41601658},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97e918b73bc2; sha256 a2e4b180e5d0ca6b41eb109e0f4ce35558fc34779a87691a64c65a5b06162bd0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41601658. Agents can read the archived copy with the MCP tool read_document.